slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 43,981-44,010
Pages 2,019
Rows per page 30
Component
43,981-44,010 of 60,568
44
EP&L stands for Environmental Profit & Loss. The slide uses a bubble matrix to show impact distribution and a line chart for intensity trends.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Transformation1 hit
47
The slide uses a consistent framework of reporting 'traceability' and 'alignment with the KS' (Kering Standards) for various raw materials.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Transformation1 hit
56
The slide outlines the SBTN 5-step process and highlights that Kering is involved in the 'Set Targets' phase for Land and Freshwater.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Transformation1 hit
05
The slide uses a table format to compare quarterly and annual guidance against prior periods.KeyCorp | Investor Conference Presentation Deck | 5 slides · KeyCorp
Conference presentation Investor relations 1 hit
06
The slide uses a standard pharmaceutical pipeline table format.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
09
Includes a mechanism of action diagram, a market data table, and a callout box on competitive limitations.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
11
Includes both a longitudinal line chart for IRAK4 degradation and a grouped bar chart with a supporting data table for cytokine inhibition.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
18
The slide provides clinical safety data for the KT-474 drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
22
Includes a table of market data and a biological pathway diagram.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
25
The slide uses a process flow diagram to illustrate the transition from dose escalation (DL1-DLx) to expansion cohorts for specific indications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
27
Data cut-off: 18 October 2023. Includes breakdown by age, sex, ECOG status, prior therapy, and tumor type.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
37
The slide uses a standard clinical trial dose-escalation diagram and a demographic table.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
45
The table displays patient counts and percentages for specific adverse events categorized by dose level (DL1-DL5) and overall.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
03
Note: Lakeland's fiscal year end is January 31Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Attention1 hit
05
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Attention1 hit
09
Slide 9 of a corporate presentation.Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Satisfaction1 hit
13
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit
14
The table provides a standard financial reconciliation for non-GAAP metrics.Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit
15
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit
06
The slide uses a simple comparison table structure to show commercial readiness.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
07
The slide uses a table-like structure to show status of four vehicle models.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Includes detailed footnotes explaining adjustments to net earnings.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations 1 hit
26
Lion Electric | Investor Presentation Deck | 31 slidesLion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations 1 hit